JUNE Medical Unveils the Galaxy II™ Slider

The most versatile surgical retractor on the market (040-21)

JUNE Medical, an award-winning medical device distributor renowned for its game-changing self-retaining retractors, is launching the Galaxy II Slider – the most versatile retractor yet.

The Galaxy II Slider is the world’s first adjustable self-retaining retractor to feature a sliding mechanism that allows surgeons to adjust the size to fit the width of the wound in situ. This makes the Galaxy II Slider an ideal solution for retracting tissue in narrow or hard to access operation sites, such as during hand surgeries, pediatrics, or procedures on patients with a high BMI.

JUNE Medical is committed to providing products that surgeons find valuable and developed the Galaxy II Slider in response to reports that standard size retractors may be more challenging to use on smaller anatomies, such as pediatric patients, or for patients with higher BMIs. The lightweight, self-retaining retractor weighs just 62 g and includes the revolutionary Cam lock system that allows for single-handed adjustment of the frame into position, and a sliding mechanism that can be securely locked into place at the correct width. This unique sliding mechanism allows surgeons to increase or decrease the tension to further separate the tissue while the surgical stay is in position, avoiding the need to reposition hooks, saving precious surgical time, and resulting in fewer skin punctures.

Rianne Mahanta, Product Manager of JUNE Medical, commented: “JUNE is proud to launch the first-ever self-retaining retractor with an adjustable sliding mechanism. This product is not only a fantastic addition to our Galaxy II range but is addressing real-world surgical problems. Although originally developed for narrow operating sites, the Galaxy II Slider is flexible and can be applied to a number of operations from hand surgeries to pediatrics.”

Angela Spang, CEO of JUNE Medical, added: “The Galaxy II Slider is another huge step for JUNE, demonstrating of our continual commitment to driving innovation and supplying functional products that are both practical and beneficial. This product is suitable for surgeries in any place, any shape, and any position, making it truly the most versatile retractor available.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”